Top

Published in:

01-12-2014 | Brief Report

Novel molecular alterations in the ORF 2 capsid gene of hepatitis E virus in patients with acute liver failure in North India

Authors: Jayanta Borkakoti, Giasuddin Ahmed, Syed Akhtar Hussain, Arvind Rai, Premashis Kar

Published in: Archives of Virology | Issue 12/2014

Abstract

Hepatitis E virus (HEV) is evolving as a major global threat to public health, including in developed countries. We partially sequenced the ORF 2 capsid protein genes of HEV genomes from patients with acute liver failure, including pregnant women in the northern part of India. Five unique synonymous substitutions and one non-synonymous substitution, along with a novel mutation, P259S, in the capsid gene, were identified that might be associated with the poor outcome in the patients. Phylogenetic analysis revealed that the isolates belonged to genotype 1 with subtype 1a. The significance of these findings for disease pathogenicity needs to be investigated further.

Dalton HR, Pas SD, Madden RG, van der Eijk AA (2014) Hepatitis E virus: current concepts and future perspectives. Curr Infect Dis Rep 16:399. doi:10.1007/s11908-014-0399-8 PubMedCrossRef

Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR (2012) Hepatitis E. Lancet 379:2477–2488PubMedCrossRef

Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR (1991) Hepatits E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185:120–131PubMedCrossRef

Tsarev SA, Emerson SU, Reyes GR, Tsareva TS, Legters LJ, Malik IA, Iqbal M, Purcell RH (1992) Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci 89:559–563PubMedCentralPubMedCrossRef

Ohnishi S, Kang JH, Maekubo H, Arakawa T, Karino Y, Toyota J, Takahashi K, Mishiro S (2006) Comparison of clinical features of acute hepatitis caused by hepatitis E virus (HEV) genotypes 3 and 4 in Sapporo, Japan. Hepatol Res 36:301–307PubMedCrossRef

Khuroo MS, Tell MR, Skidmore S, Sofi MA, Khuroo MI (1981) Incidence and severity of viral hepatitis in pregnancy. Am J Med 70:252PubMedCrossRef

Khuroo MS, Kamili S (2003) Aetiology and clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 10:61–69PubMedCrossRef

Zafrullah M, Ozdener MH, Kumar R, Panda SK, Jameel S (1999) Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. J Virol 73:4074–4082PubMedCentralPubMed

Guu TS, Liu Z, Ye Q, Mata DA, Li K, Yin C, Zhang J, Tao YJ (2009) Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci USA 106:12992–12997PubMedCentralPubMedCrossRef

10.

Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H, Shima R, Moriishi K, Tsukihara T, Li TC, Takeda N, Miyamura T, Matsuura Y (2009) Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci USA 106:12986–12991PubMedCentralPubMedCrossRef

11.

Khudyakov YE et al (1999) Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. J Clin Microbiol 37:2863–2871PubMedCentralPubMed

12.

Purcell RH, Nguyen H, Shapiro M, Engle RE, Govindarajan S, Blackwelder WC et al (2003) Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 21(19–20):2607–2615PubMedCrossRef

13.

Graff J et al (2005) In vitro and in vivo mutational analysis of the 3-terminal regions of hepatitis e virus genomes and replicons. J Virol 79:1017–1026PubMedCentralPubMedCrossRef

14.

Torresi J, Li F, Locarnini SA, Anderson DA (1999) Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. J Gen Virol 80:1185–1188PubMed

15.

Cooper K, Huang FF, Batista L, Rayo CD, Bezanilla JC, Toth TE, Meng XJ (2005) Identification of genotype 3 hepatitis E virus (HEV) in serum and fecal samples from pigs in Thailand and Mexico, where genotype 1 and 2 HEV strains are prevalent in the respective human populations. J Clin Microbiol 43:1684–2688PubMedCentralPubMedCrossRef

16.

Pugachev KV, Galinski MS, Frey TK (2000) Infectious cDNA clone of the RA27/3 vaccine strain of rubella virus. Virology 273:189–197PubMedCrossRef

17.

Van Loon AA, de Haas N, Zeyda I, Mundt E (2002) Alteration of amino acids in VP2 of very virulent infectious bursal disease virus results in tissue culture adaptation and attenuation in chickens. J Gen Virol 83:121–129PubMed

18.

Cordoba L, Huang YW, Opriessnig T, Harral KK, Beach NM, Finkielstein CV, Emerson SU, Meng XJ (2011) Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation. J Virol 85:5338–5349PubMedCentralPubMedCrossRef

19.

Trey C, Davidson CS (1970) The management of fulminant hepatic failure. Prog Liver Dis. 3:282–298PubMed

20.

Smedile A, Carcil, Verme G (1982) Influence of delta infection on severity of hepatitis B. Lancet 2:945–947PubMedCrossRef

21.

Rozen Steve, Skaletsky Helen J (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics methods and protocols: methods in molecular biology. Humana Press, Totowa, pp 365–386

22.

Jameel S, Zafrullah M, Charla YK, Dilawari J (2002) Reevaluation of a North India isolate of hepatitis E virus based on the full-length genomic sequence obtained following long RT-PCR. Virus Res 86:53–58. doi:10.1016/S0168-1702(02)00052-7 PubMedCrossRef

23.

Inoue J, Takahashi M, Mizuo H, Suzuki K, Aikawa T, Shimosegawa T, Okamoto H (2009) Nucleotide substitutions of hepatitis E virus genomes associated with fulminant hepatitis and disease severity. Tohoku J Exp Med 218:279–284PubMedCrossRef

24.

Takahashi K, Okamoto H, Abe N, Kawakami M, Matsuda H, Mochida S, Sakugawa H, Suginoshita Y, Watanabe S, Yamamoto K, Miyakawa Y, Mishiro S (2009) Virulent strain of hepatitis E virus genotype 3, Japan. Emerg Infect Dis 15:704–709. doi:10.3201/eid1505.081100 PubMedCentralPubMedCrossRef

25.

Mishra N, Walimbe AM, Arankalle VA (2012) Hepatitis E virus from India exhibits significant amino acid mutations in fulminant hepatic failure patients. Virus Genes 2013(46):47–53. doi:10.1007/s11262-012-0833-7

Title: Novel molecular alterations in the ORF 2 capsid gene of hepatitis E virus in patients with acute liver failure in North India
Authors: Jayanta Borkakoti
Giasuddin Ahmed
Syed Akhtar Hussain
Arvind Rai
Premashis Kar
Publication date: 01-12-2014
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 12/2014
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-014-2198-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Novel molecular alterations in the ORF 2 capsid gene of hepatitis E virus in patients with acute liver failure in North India

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection

A PCR-based microwell-plate hybrid capture assay for high-risk human papillomavirus

Complete genomic sequence of the Vibrio alginolyticus lytic bacteriophage PVA1

Mutations associated with severity of the pandemic influenza A(H1N1)pdm09 in humans: a systematic review and meta-analysis of epidemiological evidence

miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene

Identification of structural proteins of koi herpesvirus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page